Organ Transplant Immunosuppressant Drugs Market: Industry Analysis and forecast 2026: By Drug Class, Transplant Type, Distribution Channel and Region

Organ Transplant Immunosuppressant Drugs Market: Industry Analysis and forecast 2026: By Drug Class, Transplant Type, Distribution Channel and Region

Market Scenario

Organ Transplant Immunosuppressant Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026. Organ Transplant Immunosuppressant Drugs Market Organ Transplant Immunosuppressant Drugs Market Drivers and Restrains: Successful transplantations have been performed for the kidneys, liver, heart, lungs, pancreas, thymus, and intestine. Kidney transplants are the most common as compared to liver and heart transplants. Organ transplant immunosuppressant drugs are the class of drugs which are managed to reduce the risks of organ rejection after transplantation. When a person experiences any transplantation, the body recognizes the transplant as a foreign tissue and attacks it, resulting in rejection. These drugs dilute the immune system, hence fuel demand for advanced immunosuppressant drugs to prevent organ rejection post-transplantation. These transplantations help in the survival of many patients as well as enhance the quality of life. The organ transplant immunosuppressant drugs market has driven by such factors are technological advancements in organ transplants, tissue engineering and increasing incidences of chronic diseases leading to organ failure and disabilities. According to the U.S. Department of Health and Human Services, Health Resources & Services Administration, XX transplants were executed in 2018 and more than XX people required transplants as of next year. However, high cost of procedure and inadequate, lack of donor organs and the advent of stem cells are the major restraining factor of the market growth at the global level. Novel medication options and the increase in the use of tissue engineering for the generation of implants are provided growth opportunity in the organ transplant immunosuppressant drugs market. Organ Transplant Immunosuppressant Drugs Market Segmentation Analysis: Based on the transplant type, the organ transplant immunosuppressant drugs market has been segmented into Kidney, Liver, Heart, Lung, and Pancreas. The kidney transplant segment held the largest market share in 2018 due to increasing demand and relatively better organ availability than other transplants. Kidney transplantation has developed as the most preferred treatment method for end-stage renal diseases and it has proven more cost-effective than prolonged periods of dialysis. The liver and heart transplants segments are also expected to grow at the highest CAGR of XX% in the near future due to the current rate of adoption and future growth prospects. Heart transplantation is currently regarded as the gold standard of treatment as it has revolutionized end-stage heart failure therapy. The liver transplantation has become a life-saving technique for patients with chronic end stage liver disease and selected patients with acute liver failure (ALF) and alcoholic liver disease (ALD). Based on the distribution channel, the organ transplant immunosuppressant drugs market has been segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In terms of revenue the hospital pharmacies and retail pharmacies segments held the dominant market share in 2018, because of hospital pharmacies offer easy and rapid access, while retail pharmacies usually have sufficient products in stock. Online pharmacies segments are expected to grow at the largest CAGR of XX% during the upcoming period owing to the growing popularity of eCommerce channels for obtaining prescribed immunosuppressant drugs. Online pharmacies offer a wide range of options and in-depth information about these drugs, due to which an increasing consumer preference for online channels. Organ Transplant Immunosuppressant Drugs Market Regional Analysis: Geographically, the organ transplant immunosuppressant drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe held the largest market share of XX% in 2018 due to the higher number of organ transplantations conducted in the region, the recent improvements in surgical techniques, technology, and immunosuppressant drug discovery. The high healthcare expenditure, established R&D infrastructure, favorable healthcare reimbursement policies and huge demand for organ transplants, these factors are driving the regional market growth. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period due to an increasing revenue generation from calcineurin inhibitors and mTOR inhibitors in this region. Encouraging initiatives pertaining to the increasing investments by the governments and manufacturers in the healthcare sector and sufficiently new opportunities are the key factors impelling the market growth in this region. A report covers the recent development in market for the organ transplant immunosuppressant drugs market like, In November 2018, Veloxis Pharmaceuticals in association with Temple University, began a phase IV clinical trial of tacrolimus for use in kidney transplant recipients and its completion was expected by August 2019. Organ Transplant Immunosuppressant Drugs Market Competitive landscape Major Key players operating in this market are Astellas Pharma Inc, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc. and Novartis AG. Manufacturers in the organ transplant immunosuppressant drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present comprehensive analysis of organ transplant immunosuppressant drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding organ transplant immunosuppressant drugs market dynamics, structure by analyzing the market segments, and project the organ transplant immunosuppressant drugs market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the organ transplant immunosuppressant drugs market make the report investor’s guide.

Scope of the Organ Transplant Immunosuppressant Drugs Market:

Organ Transplant Immunosuppressant Drugs Market, by Drug Class

• Calcineurin Inhibitors • Antiproliferative Agents • mTOR Inhibitor • Steroids • Antibodies

Organ Transplant Immunosuppressant Drugs Market, by Transplant Type

• Kidney • Liver • Heart • Lung • Pancreas

Organ Transplant Immunosuppressant Drugs Market, by Distribution Channel

• Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

Organ Transplant Immunosuppressant Drugs Market, by Region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Organ Transplant Immunosuppressant Drugs Market, Major Players

• Astellas Pharma Inc, • Genzyme Corporation • Accord Healthcare Ltd. • Watson Pharmaceuticals, Inc. • Novartis AG • Mylan Laboratories, Inc. • GlaxoSmithKline plc • Hoffman La Roche. • Sanofi • F. Hoffmann-La Roche Ltd. • Veloxis Pharmaceuticals A/S • Bristol-Myers Squibb Company. • Pfizer • Terumo Corporation • Transmed • Transonic • Preservation Solutions Inc. • Organ Recovery Systems • XVIVO Perfusion Global Dental Chair Market

Table of Contents

Organ Transplant Immunosuppressant Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Organ Transplant Immunosuppressant Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast 6.1. Global Organ Transplant Immunosuppressant Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Drug Class 7.4. Global Organ Transplant Immunosuppressant Drugs Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Organ Transplant Immunosuppressant Drugs Market Analysis, by Drug Class 7.6. Global Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis, by Drug Class 8. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast, by Transplant Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Transplant Type 8.4. Global Organ Transplant Immunosuppressant Drugs Market Size (US$ Bn) Forecast, by Transplant Type 8.5. Global Organ Transplant Immunosuppressant Drugs Market Analysis, by Transplant Type 8.6. Global Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis, by Transplant Type 9. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Distribution Channel 9.4. Global Organ Transplant Immunosuppressant Drugs Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Global Organ Transplant Immunosuppressant Drugs Market Analysis, by Distribution Channel 9.6. Global Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis, by Distribution Channel 10. Global Organ Transplant Immunosuppressant Drugs Market Analysis, by Region 10.1. Global Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Region 10.2. Global Organ Transplant Immunosuppressant Drugs Market Size (US$ Bn) Forecast, by Region 10.3. Global Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis, by Region 11. North America Organ Transplant Immunosuppressant Drugs Market Analysis 11.1. Key Findings 11.2. North America Organ Transplant Immunosuppressant Drugs Market Overview 11.3. North America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Drug Class 11.4. North America Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 11.4.1. Calcineurin Inhibitors 11.4.2. Antiproliferative Agents 11.4.3. mTOR Inhibitor 11.4.4. Steroids 11.4.5. Antibodies 11.5. North America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Transplant Type 11.6. North America Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 11.6.1. Kidney 11.6.2. Liver 11.6.3. Heart 11.6.4. Lung 11.6.5. Pancreas 11.7. North America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Distribution Channel 11.8. North America Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Online Pharmacies 11.9. North America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Country 11.10. North America Organ Transplant Immunosuppressant Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Organ Transplant Immunosuppressant Drugs Market Analysis, by Country 11.12. U.S. Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 11.12.1. Calcineurin Inhibitors 11.12.2. Antiproliferative Agents 11.12.3. mTOR Inhibitor 11.12.4. Steroids 11.12.5. Antibodies 11.13. U.S. Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 11.13.1. Kidney 11.13.2. Liver 11.13.3. Heart 11.13.4. Lung 11.13.5. Pancreas 11.14. U.S. Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Canada Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 11.15.1. Calcineurin Inhibitors 11.15.2. Antiproliferative Agents 11.15.3. mTOR Inhibitor 11.15.4. Steroids 11.15.5. Antibodies 11.16. Steel Canada Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 11.16.1. Kidney 11.16.2. Liver 11.16.3. Heart 11.16.4. Lung 11.16.5. Pancreas 11.17. Canada Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Pharmacies 11.18. North America Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Transplant Type 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Organ Transplant Immunosuppressant Drugs Market Analysis 12.1. Key Findings 12.2. Europe Organ Transplant Immunosuppressant Drugs Market Overview 12.3. Europe Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Drug Class 12.4. Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.4.1. Calcineurin Inhibitors 12.4.2. Antiproliferative Agents 12.4.3. mTOR Inhibitor 12.4.4. Steroids 12.4.5. Antibodies 12.5. Europe Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Transplant Type 12.6. Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.6.1. Kidney 12.6.2. Liver 12.6.3. Heart 12.6.4. Lung 12.6.5. Pancreas 12.7. Europe Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Distribution Channel 12.8. Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Online Pharmacies 12.9. Europe Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Country 12.10. Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Organ Transplant Immunosuppressant Drugs Market Analysis, by Country 12.12. Germany Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.12.1. Calcineurin Inhibitors 12.12.2. Antiproliferative Agents 12.12.3. mTOR Inhibitor 12.12.4. Steroids 12.12.5. Antibodies 12.13. Germany Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.13.1. Kidney 12.13.2. Liver 12.13.3. Heart 12.13.4. Lung 12.13.5. Pancreas 12.14. Germany Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail Pharmacies 12.14.3. Online Pharmacies 12.15. U.K. Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.15.1. Calcineurin Inhibitors 12.15.2. Antiproliferative Agents 12.15.3. mTOR Inhibitor 12.15.4. Steroids 12.15.5. Antibodies 12.16. U.K. Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.16.1. Kidney 12.16.2. Liver 12.16.3. Heart 12.16.4. Lung 12.16.5. Pancreas 12.17. U.K. Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. France Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.18.1. Calcineurin Inhibitors 12.18.2. Antiproliferative Agents 12.18.3. mTOR Inhibitor 12.18.4. Steroids 12.18.5. Antibodies 12.19. France Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.19.1. Kidney 12.19.2. Liver 12.19.3. Heart 12.19.4. Lung 12.19.5. Pancreas 12.20. France Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail Pharmacies 12.20.3. Online Pharmacies 12.21. Italy Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.21.1. Calcineurin Inhibitors 12.21.2. Antiproliferative Agents 12.21.3. mTOR Inhibitor 12.21.4. Steroids 12.21.5. Antibodies 12.22. Italy Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.22.1. Kidney 12.22.2. Liver 12.22.3. Heart 12.22.4. Lung 12.22.5. Pancreas 12.23. Italy Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Online Pharmacies 12.24. Spain Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.24.1. Calcineurin Inhibitors 12.24.2. Antiproliferative Agents 12.24.3. mTOR Inhibitor 12.24.4. Steroids 12.24.5. Antibodies 12.25. Spain Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.25.1. Kidney 12.25.2. Liver 12.25.3. Heart 12.25.4. Lung 12.25.5. Pancreas 12.26. Spain Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail Pharmacies 12.26.3. Online Pharmacies 12.27. Rest of Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 12.27.1. Calcineurin Inhibitors 12.27.2. Antiproliferative Agents 12.27.3. mTOR Inhibitor 12.27.4. Steroids 12.27.5. Antibodies 12.28. Rest of Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 12.28.1. Kidney 12.28.2. Liver 12.28.3. Heart 12.28.4. Lung 12.28.5. Pancreas 12.29. Rest Of Europe Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail Pharmacies 12.29.3. Online Pharmacies 12.30. Europe Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Transplant Type 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Overview 13.3. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 13.4.1. Calcineurin Inhibitors 13.4.2. Antiproliferative Agents 13.4.3. mTOR Inhibitor 13.4.4. Steroids 13.4.5. Antibodies 13.5. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Transplant Type 13.6. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 13.6.1. Kidney 13.6.2. Liver 13.6.3. Heart 13.6.4. Lung 13.6.5. Pancreas 13.7. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Online Pharmacies 13.9. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Analysis, by Country 13.12. China Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 13.12.1. Calcineurin Inhibitors 13.12.2. Antiproliferative Agents 13.12.3. mTOR Inhibitor 13.12.4. Steroids 13.12.5. Antibodies 13.13. China Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 13.13.1. Kidney 13.13.2. Liver 13.13.3. Heart 13.13.4. Lung 13.13.5. Pancreas 13.14. China Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. India Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 13.15.1. Calcineurin Inhibitors 13.15.2. Antiproliferative Agents 13.15.3. mTOR Inhibitor 13.15.4. Steroids 13.15.5. Antibodies 13.16. India Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 13.16.1. Kidney 13.16.2. Liver 13.16.3. Heart 13.16.4. Lung 13.16.5. Pancreas 13.17. India Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Japan Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 13.18.1. Calcineurin Inhibitors 13.18.2. Antiproliferative Agents 13.18.3. mTOR Inhibitor 13.18.4. Steroids 13.18.5. Antibodies 13.19. Japan Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 13.19.1. Kidney 13.19.2. Liver 13.19.3. Heart 13.19.4. Lung 13.19.5. Pancreas 13.20. Japan Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Online Pharmacies 13.21. ASEAN Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 13.21.1. Calcineurin Inhibitors 13.21.2. Antiproliferative Agents 13.21.3. mTOR Inhibitor 13.21.4. Steroids 13.21.5. Antibodies 13.22. ASEAN Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 13.22.1. Kidney 13.22.2. Liver 13.22.3. Heart 13.22.4. Lung 13.22.5. Pancreas 13.23. ASEAN Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Online Pharmacies 13.24. Rest of Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 13.24.1. Calcineurin Inhibitors 13.24.2. Antiproliferative Agents 13.24.3. mTOR Inhibitor 13.24.4. Steroids 13.24.5. Antibodies 13.25. Rest of Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 13.25.1. Kidney 13.25.2. Liver 13.25.3. Heart 13.25.4. Lung 13.25.5. Pancreas 13.26. Rest of Asia Pacific Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Online Pharmacies 13.27. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Transplant Type 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Overview 14.3. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 14.4.1. Calcineurin Inhibitors 14.4.2. Antiproliferative Agents 14.4.3. mTOR Inhibitor 14.4.4. Steroids 14.4.5. Antibodies 14.5. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Transplant Type 14.6. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 14.6.1. Kidney 14.6.2. Liver 14.6.3. Heart 14.6.4. Lung 14.6.5. Pancreas 14.7. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Online Pharmacies 14.9. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Analysis, by Country 14.12. GCC Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 14.12.1. Calcineurin Inhibitors 14.12.2. Antiproliferative Agents 14.12.3. mTOR Inhibitor 14.12.4. Steroids 14.12.5. Antibodies 14.13. GCC Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 14.13.1. Kidney 14.13.2. Liver 14.13.3. Heart 14.13.4. Lung 14.13.5. Pancreas 14.14. GCC Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Online Pharmacies 14.15. South Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 14.15.1. Calcineurin Inhibitors 14.15.2. Antiproliferative Agents 14.15.3. mTOR Inhibitor 14.15.4. Steroids 14.15.5. Antibodies 14.16. South Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 14.16.1. Kidney 14.16.2. Liver 14.16.3. Heart 14.16.4. Lung 14.16.5. Pancreas 14.17. South Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. Rest of Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 14.18.1. Calcineurin Inhibitors 14.18.2. Antiproliferative Agents 14.18.3. mTOR Inhibitor 14.18.4. Steroids 14.18.5. Antibodies 14.19. Rest of Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 14.19.1. Kidney 14.19.2. Liver 14.19.3. Heart 14.19.4. Lung 14.19.5. Pancreas 14.20. Rest of Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Online Pharmacies 14.21. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Transplant Type 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Organ Transplant Immunosuppressant Drugs Market Analysis 15.1. Key Findings 15.2. South America Organ Transplant Immunosuppressant Drugs Market Overview 15.3. South America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Drug Class 15.4. South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 15.4.1. Calcineurin Inhibitors 15.4.2. Antiproliferative Agents 15.4.3. mTOR Inhibitor 15.4.4. Steroids 15.4.5. Antibodies 15.5. South America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Transplant Type 15.6. South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 15.6.1. Kidney 15.6.2. Liver 15.6.3. Heart 15.6.4. Lung 15.6.5. Pancreas 15.7. South America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Distribution Channel 15.8. South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Online Pharmacies 15.9. South America Organ Transplant Immunosuppressant Drugs Market Value Share Analysis, by Country 15.10. South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Organ Transplant Immunosuppressant Drugs Market Analysis, by Country 15.12. Brazil Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 15.12.1. Calcineurin Inhibitors 15.12.2. Antiproliferative Agents 15.12.3. mTOR Inhibitor 15.12.4. Steroids 15.12.5. Antibodies 15.13. Brazil Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 15.13.1. Kidney 15.13.2. Liver 15.13.3. Heart 15.13.4. Lung 15.13.5. Pancreas 15.14. Brazil Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Online Pharmacies 15.15. Mexico Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 15.15.1. Calcineurin Inhibitors 15.15.2. Antiproliferative Agents 15.15.3. mTOR Inhibitor 15.15.4. Steroids 15.15.5. Antibodies 15.16. Mexico Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 15.16.1. Kidney 15.16.2. Liver 15.16.3. Heart 15.16.4. Lung 15.16.5. Pancreas 15.17. Mexico Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. Rest of South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Drug Class 15.18.1. Calcineurin Inhibitors 15.18.2. Antiproliferative Agents 15.18.3. mTOR Inhibitor 15.18.4. Steroids 15.18.5. Antibodies 15.19. Rest of South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Transplant Type 15.19.1. Kidney 15.19.2. Liver 15.19.3. Heart 15.19.4. Lung 15.19.5. Pancreas 15.20. Rest of South America Organ Transplant Immunosuppressant Drugs Market Forecast, by Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Online Pharmacies 15.21. South America Organ Transplant Immunosuppressant Drugs Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Transplant Type 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Astellas Pharma Inc 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Genzyme Corporation 16.3.3. Accord Healthcare Ltd. 16.3.4. Watson Pharmaceuticals, Inc. 16.3.5. Novartis AG 16.3.6. Mylan Laboratories, Inc. 16.3.7. GlaxoSmithKline plc 16.3.8. Hoffman La Roche. 16.3.9. Sanofi 16.3.10. F. Hoffmann-La Roche Ltd. 16.3.11. Veloxis Pharmaceuticals A/S 16.3.12. Bristol-Myers Squibb Company. 16.3.13. Pfizer 16.3.14. Terumo Corporation 16.3.15. Transmed 16.3.16. Transonic 16.3.17. Preservation Solutions Inc. 16.3.18. Organ Recovery Systems 16.3.19. XVIVO Perfusion 17. Primary Key Insights

About This Report

Report ID38792
Published DateNov 2019
Contact Us
Call Now